CLIENT NAME

Phone: 121-454-5555
email@yahoo.com

SENIOR SCIENTIST

Biochemist | Assay Development

Diligent, innovative, **Award-Winning Senior Scientist** with years of experience in drug discovery and who has served as a vital member of a lead optimization team; a very talented Enzymologist in the area of quantitative molecular pharmacology and a versatile and flexible team player who delivers new ideas and bench work. Persuasive communicator who excels at giving high-level presentations that motivates others to take initiative and work harder to achieve established goals and objectives. Demonstrated expertise in: enzyme kinetics, assay development, characterization of inhibitors, analytical and preparative HPLC. Leadership roles included:

- **Lead Small Molecule Bioanalytical Group**; organized database of analytical methods, identified bottlenecks in the process and needs for new equipment
- **Lead departmental meetings, organized speakers and agenda**
- **Managed a multidisciplinary process** for gram-scale enzymatic synthesis and purification of commercially unavailable peptidoglycan precursors-substrates for high throughput enzyme assays and was able to reduce the assay development costs by more than $100,000 dollars

A combination of amazing leadership and communication skills, along with proven results managing processes which involved staff from varied scientific disciplines, creates the perfect level of experience necessary to embrace a challenging role of a Senior Scientist who also has the responsibility for supervising Junior Scientists.

HONORS AND AWARDS

2012 **Senior Scientist of the Year (AstraZeneca Global Award)**
- For discovery of a novel mechanism of inhibition for a β-lactamase inhibitor, avibactam

2011 **Exceptional Team Achievement (Infection Function)**
- For contribution to research on β-lactamase inhibition and impact on chemistry plan

2007 **On the Spot Award (Infection Function)**
Recognition for innovation, initiative, good citizenship, going beyond expectations in a way that is not connected to performance goals
- For development of a novel supercoiling assay for DNA gyrase

2005 **Exceptional Achievement (Infection Function)**
For progressing a project through innovated scientific skill
- Method development and large-scale purification of libraries of small molecule inhibitors from complex mixtures
- Contribution to intellectual property coverage for DNA ligase project

2004 **Special Collaborative Team Contribution in Infection 2004 (Infection Function)**
- For outstanding development of novel screening assays to a UK based HTS laboratory

2004 **On the Spot Award**
- For enzymatic synthesis and purification of a small molecule activator for an Infection project

2002 **On the Spot Award**
- For method development and purification of a secondary assay reagent (MESG)

EDUCATION

Northeastern University, Boston MA, Master of Science
Coursework in Chemical Biology
Completed courses include: Chemical Biology, Advanced Analytical Separations, Drug Discovery and Development, Analytical Biochemistry, Protein Chemistry, Special Topics in Organic Chemistry (Designing Protein Therapeutics, Directed Research), Pharmacokinetics and Pharmacodynamics; Expected May 2015

University of Illinois, Urbana-Champaign
- Bachelor of Science with Distinction in Molecular and Integrative Physiology

Howard Hughes Undergraduate Research Fellowship
- Senior Thesis and poster presentation: Isolation and Cloning of Canine MMP-2

University of Sarajevo Medical School (interrupted by the war of 1992)
Coursework completed: Human Anatomy, Physiology, Biochemistry, Histology & Embryology, Medicinal Chemistry, Biology and Genetics, Biophysics, Sociology

ACS Courses: Antibiotics and Antibacterial Agents, The Organic Chemistry of Drug Design and Drug Action, LC-MS Fundamentals

CAREER HIGHLIGHTS

Championed a novel lead optimization strategy involving the use of antibody-drug conjugates (ADCs) in the treatment of infections; initiated and facilitate the collaboration of two AstraZeneca research sites, 1) in Gaithersburg MD, working on immunotherapies and 2) a Boston research site working on small molecule-based therapies. This project remains active.

PROFESSIONAL EXPERIENCE

2000-2014: Infection Innovative Medicines, AstraZeneca R&D Boston
Independent Contributions, Leadership Roles and Committees:
- Initiated and organized collaborations and international work assignments
- Proposed and implemented novel strategies for lead generation
- Engaged in conversations with Astrazeneca's CEO, Pascal Soriot and Chairman of the Board, Leif Johansson during their site visits, as a member of the Welcoming Committee
- Developed publication guidelines as a member of the Infection Publications Committee
- Chaired Infection Innovation Days, organized conference for external guest speakers and scientists from the global AstraZeneca organization

Contributions to multidisciplinary project teams in lead discovery:
Target Evaluation Team
Enabled biochemical evaluation of novel drug targets and drug candidates by maintaining a constant supply of high quality reagents and substrates:
- Managed procurement of reagents through CROs
- Evaluated screening technology and determined apparent and mechanism-specific kinetic constants for enzyme targets
- Developed novel assays for enzymes intended for high throughput screening (HTS)

Assay Development and Transfer Team
Progressed projects from target evaluation to hit evaluation milestones:
- Coordinated with an automation group in the UK on a weekly basis to ensure flawless assay transfer and scale up on automation equipment

PROFESSIONAL EXPERIENCE CONT:

Hit Evaluation and Lead Identification
Managed biochemical evaluation of hits from HTS:

- Developed and implemented testing cascades with secondary functional and binding assays
- Conducted mode of inhibition studies on promising leads
- Presented data in interdisciplinary team environment and influenced go/no go decisions regarding the transition to Lead Optimization stage

Lead optimization Teams
Biochemist on the Core Lead Optimization Team; Influenced selection of chemical scaffolds and synthesis of novel compounds:

- Determined relative potencies (IC50) for lead compounds toward optimization of the structure-activity relationship (SAR)
- Determined on and off rate kinetics for lead compounds toward optimization of the structure-kinetic relationship (SKR)
- Elucidated modes of inhibition through functional and binding (ITC) assays
- Designed strategies for improvement of inhibitor potency

2000: Contractor Researcher, Molecular Sciences, Pfizer Global R&D, Ann Arbor, MI

- Cultured mammalian cells for production of enzyme necessary for assay development and HTS
- Performed site-directed mutagenesis for characterization of enzymes and inhibitors

COMMUNITY SERVICE/VOLUNTEER EXPERIENCE

Zenica City Hospital, Bosnia and Herzegovina
Emergency Room Medic

- Provided treatment for cuts and superficial shrapnel wounds

PUBLICATIONS & PATENTS

Listed out on actual CV but remains confidential in this sample

REFERENCES

Available Upon Request